Combination romidepsin and azacitidine therapy is well tolerated and clinically active in adults with high‐risk acute myeloid leukaemia ineligible for intensive chemotherapy

Loke, J. et al. (2022) Combination romidepsin and azacitidine therapy is well tolerated and clinically active in adults with high‐risk acute myeloid leukaemia ineligible for intensive chemotherapy. British Journal of Haematology, 196(2), pp. 368-373. (doi: 10.1111/bjh.17823) (PMID:34490623)

Abstract

Azacitidine (AZA) is important in the management of patients with acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy. Romidepsin (ROM) is a histone deacetylase inhibitor which synergises with AZA in vitro. The ROMAZA trial established the maximum tolerated dose (MTD) of combined ROM/AZA therapy in patients with AML, as ROM 12 mg/m2 on Days 8 and 15, with AZA 75 mg/m2 administered for 7/28 day cycle. Nine of the 38 (23·7%) patients treated at the MTD were classified as responders by Cycle 6 (best response: complete remission [CR]/incomplete CR n = 7, partial response n = 2). Correlative next‐generation sequencing studies demonstrated important insights into therapy resistance.

• Item Type: Articles
• Keywords: Acute myeloid leukaemia, relapsed, refractory, early phase, clinical trial, hypomethylating agent.
• Status: Published
• Refereed: Yes
• Glasgow Author(s) Enlighten ID: Drummond, Dr Mark
• Authors: Loke, J., Metzner, M., Boucher, R., Jackson, A., Hopkins, L., Pavlu, J., Tholouli, E., Drummond, M., Peniket, A., Bishop, R., Fox, S., Vyas, P., and Craddock, C.
• College/School: College of Medical Veterinary and Life Sciences > School of Medicine, Dentistry & Nursing
• Journal Name: British Journal of Haematology
• Publisher: Wiley
• ISSN: 0007-1048
• ISSN (Online): 1365-2141
• Published Online: 06 September 2021
• Copyright Holders: Copyright © 2021 The Authors
• First Published: First published in British Journal of Haematology 196(2): 368-373
• Publisher Policy: Reproduced under a Creative Commons License